## Interactions with Lenacapavir

Initiated within 9 months after stopping subcutaneous LEN. Residual LEN may affect exposure of sensitive CYP3A4 substrates.

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Anxiolytics</th>
<th>ATV/c</th>
<th>ATV/r</th>
<th>DRV/c</th>
<th>DRV/r</th>
<th>LPV/r</th>
<th>Dor</th>
<th>EFV</th>
<th>TDF</th>
<th>3TC</th>
<th>NVP</th>
<th>ETV</th>
<th>NAV</th>
<th>ETR</th>
<th>RAL</th>
<th>BIC</th>
<th>FTC</th>
<th>TAF</th>
<th>TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprazolam</td>
<td>↑</td>
<td>↑</td>
<td>a</td>
<td>↑</td>
<td>a</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Bromazepam</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>a</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Buspirone</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Clorazepate</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Diazepam</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Oxazepam</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Midazolam</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓18%</td>
<td>b</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Temazepam</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Triazolam</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>e+</td>
<td>b</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Valerian</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Zaleplon</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Zolpidem</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
<tr>
<td>Zopiclone</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>e+</td>
<td>↓</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
<td>e+</td>
</tr>
</tbody>
</table>

### Notes

- **a** Initial inhibitory effect followed by inductive effect in presence of ritonavir. Start alprazolam at a lower dose and increase if needed.
- **b** The efavirenz European SPC (but no longer the US Prescribing Information) contraindicates coadministration citing competition for CYP3A4 by efavirenz as a potential mechanism for inhibition of midazolam or triazolam metabolism which may result in potential serious and/or life-threatening adverse events.

### Interactions with CAB/RPV long acting injections

Pharmacokinetic interactions shown are mostly with RPV.

**Interactions with Lenacapavir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Itibazumab**

None

### Interactions with Abacavir (ABC), Lamivudine (3TC), Tenofovir-OF (TDF) or Zidovudine (ZDV)

ABC: No clinically relevant interactions expected.

3TC: No clinically relevant interactions expected.

TDF: No clinically relevant interactions expected.

ZDV: No clinically relevant interactions expected.

### Colour Legend

- **No clinically significant interaction expected.**
- **These drugs should not be coadministered.**
- **Potential interaction which may require a dose adjustment or close monitoring.**
- **Potential interaction predicted to be of weak intensity.**
- **No a priori dosage adjustment is recommended.**

### Text Legend

- **↑** Potential increased exposure of the anxiolytic/hypnotic
- **↓** Potential decreased exposure of the anxiolytic/hypnotic
- **↔** No significant effect

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

### Abbreviations

- **ATV** atazanavir
- **EFV** efavirenz
- **RPV** raltegravir
- **TDF** tenofovir DF
- **FTC** emtricitabine
- **TAF** tenofovir alafenamide
- **ABC** abacavir
- **3TC** lamivudine
- **LEN** lenacapavir
- **LVP** lopinavir
- **DOR** doravirine
- **NVP** nevirapine
- **ETV** etravirine
- **NVP** nevirapine
- **ZDV** zidovudine
- **DOR** doravirine
- **EFV** efavirenz
- **ETV** etravirine
- **NVP** nevirapine
- **ZDV** zidovudine
- **LEN** lenacapavir
- **LVP** lopinavir
- **DOR** doravirine
- **NVP** nevirapine
- **ETV** etravirine
- **NVP** nevirapine
- **ZDV** zidovudine
- **LEN** lenacapavir
- **LVP** lopinavir
- **DOR** doravirine
- **NVP** nevirapine
- **ETV** etravirine
- **NVP** nevirapine
- **ZDV** zidovudine

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool. L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise however or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.